Cipla Q2FY27: Revenue INR 7,404 Cr, EBITDA margin 18.7%, record One India quarter and U.S. FDA nod for gAdvair Diskus
Q2FY27 revenue INR 7,404 Cr vs 7,589; EBITDA INR 1,388 Cr at 18.7% margin vs 25.0%; PAT INR 878 Cr.
By ScoutQuest · · 1 min read
- Q2FY27 Revenue
- INR 7,404 Cr vs 7,589
- EBITDA
- INR 1,388 Cr at 18.7% margin vs 25.0%
- PAT
- INR 878 Cr
- Period
- Q2FY27
- Positioning
- Cipla describes itself as the largest pharma company by volume in the Indian market, #2 in the chronic segment, with One India at 48% of revenue alongside North America, Africa and emerging markets.
📉 Q2FY27 revenue from operations was INR 7,404 Cr against INR 7,589 Cr a year earlier; EBITDA fell to INR 1,388 Cr (18.7% margin) from INR 1,895 Cr (25.0%), and PAT to INR 878 Cr from INR 1,351 Cr. R&D spend was INR 423 Cr, 5.7% of revenue.
🌍 One India posted its highest-ever quarterly revenue of INR 3,516 Cr, up 12% YoY, and the company says it held #2 rank in the chronic segment and is the largest pharma company by volume in India. North America revenue was $ 172 Mn, One Africa $ 123 Mn and Emerging Markets & Europe $ 101 Mn.
🌍 The presentation lists new strategic alliances: an exclusive licence with CTTQ for bispecific HER2 ADC TQB2102 across India, South Africa and five other emerging markets, and an exclusive U.S. partnership with Qilu for a Keytruda biosimilar, subject to regulatory approval. It also cites U.S. FDA approval for gAdvair Diskus.
💰 The balance sheet shows equity of INR 35,522 Cr, cash and equivalents of INR 10,522 Cr and total debt of INR 699 Cr at Sep-26. Management states FY 2029-30 ESG goals including 80% renewable electricity for India manufacturing, with 77% reported so far.
Also from Cipla
Cipla reported modest Q2 numbers but maintained its US revenue and EBITDA margin guidance, prompting mixed brokerage reactions
28 Oct 2026
Cipla posts audio recording of Q2/H1 FY27 earnings conference call on its website
27 Oct 2026
Cipla's Q2 results were largely in line with estimates, with a dip in profit and muted US sales due to supply issues
27 Oct 2026
More numbers
- Revenue from operations, Q2FY27INR 7,404 Cr
- Revenue from operations, Q2FY267,589 (INR Cr)
- EBITDA, Q2FY27INR 1,388 Cr
- EBITDA margin, Q2FY2718.7%
- EBITDA margin, Q2FY2625.0%
- PAT, Q2FY27INR 878 Cr
- PAT, Q2FY261,351 (INR Cr)
- One India revenue, Q2FY27INR 3,516 Cr
- One India YoY growth, Q2FY2712%
- R&D spend, Q2FY27INR 423 Cr
- Cash and cash equivalents, Sep-2610,522 (INR Cr)
- Total debt, Sep-26699 (INR Cr)
- Equity, Sep-2635,522 (INR Cr)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.